Skip to main content
Iris Isufi, MD, Oncology, New Haven, CT, Yale-New Haven Hospital

IrisIsufiMD

Oncology New Haven, CT

Assistant Professor, Comprehensive Cancer Center, Yale University School of Medicine

Dr. Isufi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Isufi's full profile

Already have an account?

Education & Training

  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
  • Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)
    Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2007
  • Stony Brook University Health Sciences Center School of Medicine
    Stony Brook University Health Sciences Center School of MedicineClass of 2004

Certifications & Licensure

  • CT State Medical License
    CT State Medical License 2011 - 2025
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...
    Iris Isufi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
    Iris Isufi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma
    Iris Isufi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Press Mentions

  • Oncternal Therapeutics : Lee 2022 ASCO Poster Zilovertamab + Ibrutinib for MCL and CLL
    Oncternal Therapeutics : Lee 2022 ASCO Poster Zilovertamab + Ibrutinib for MCL and CLLJune 7th, 2022

Professional Memberships

Hospital Affiliations